SCHEMBL1733359

SCHEMBL1733359

CNc1nc(C(N)=O)cc(-c2cccc(OC)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 5/20 0.50
ADORA2A P29274 4/20 0.50
ADORA3 P0DMS8 2/20 0.50
ADORA2B P29275 2/20 0.50
PLK1 P53350 1/20 0.48
IKBKB O14920 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
NPC1 O15118 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MAPT P10636 1/20 0.46
VCP P55072 1/20 0.46
GLA P06280 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CNR2 P34972 1/20 0.45
PARP1 P09874 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734123 0.87 VCP (0.51) ADORA1ADORA2AADORA3ADORA2BIKBKB
SCHEMBL1734170 0.84 VCP (0.51) ADORA1ADORA2AADORA3ADORA2BIKBKB
SCHEMBL1733528 0.83 ADORA1 (0.60) ADORA1ADORA2AADORA3ADORA2BIKBKB
SCHEMBL1734512 0.83 VCP (0.48) ADORA1ADORA2AADORA3ADORA2BPLK1
SCHEMBL1734129 0.83 VCP (0.48) ADORA1ADORA2AADORA3ADORA2BIKBKB
SCHEMBL1733664 0.83 TDP1 (0.65) ADORA1ADORA2AADORA3ADORA2BSMN1; SMN2
SCHEMBL1734639 0.82 VCP (0.70) VCP
SCHEMBL1734586 0.81 KDM4E (0.66) ADORA1ADORA2AADORA3ADORA2BSMN1; SMN2
SCHEMBL1733546 0.80 KDM4E (0.52) ADORA1ADORA2AADORA3ADORA2BPLK1
SCHEMBL1733485 0.78 VCP (0.49) ADORA1ADORA2AADORA3ADORA2BIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 ADORA1 142/4885ADORA2A 161/4885ADORA3 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.